Oncode Scientific Sdn Bhd
201501029484 (1154805-X)
Leading the Precision Medicine Revolution in Asia
Since 2015, Oncode Scientific Sdn Bhd has emerged as a trailblazer in the realm of precision medicine, setting new benchmarks in cancer molecular diagnostics. Our multidisciplinary team, comprising top-tier experts from molecular science and clinical practice, brings together decades of experience in medical diagnostics and research. At our cutting-edge facilities in Malaysia, we spearhead one of Asia’s most pioneering precision medicine initiatives, specializing in both solid tumors and hematologic cancers. Our relentless pursuit of innovation drives us to constantly challenge the status quo, exceeding clinical and diagnostic standards to deliver groundbreaking medical solutions. Oncode is dedicated to transforming healthcare—advancing disease prevention, early detection, and targeted intervention. With a commitment to excellence, we provide world-class molecular diagnostic services that are both accessible and revolutionary, empowering the global community to embrace the full potential of precision medicine.
12/01/2026
On 30th September 2025, Oncode had the privilege of engaging with the Oncology and Radiotherapy Department at Hospital Kuala Lumpur (HKL).
We shared how Oncode’s flexible and customisable panel options deliver high-quality molecular testing at accessible pricing—empowering clinicians with the tools they need for informed decision-making.
A key focus of the session was the critical role of genetic counselling in germline testing. At Oncode, all germline tests are paired with professional genetic counselling, ensuring patients receive not just results, but the support and clarity needed to navigate them confidently.
06/01/2026
From decoding rare mutations to empowering patients with knowledge — 𝗚𝗖𝗔𝗗-𝗡𝗙𝗔𝗗 𝟮𝟬𝟮𝟱 reminded us why genetics is at the heart of precision care.
Oncode was proud to participate in the 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗖𝗼𝘂𝗻𝘀𝗲𝗹𝗹𝗼𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗗𝗮𝘆 & 𝗡𝗲𝘂𝗿𝗼𝗳𝗶𝗯𝗿𝗼𝗺𝗮𝘁𝗼𝘀𝗶𝘀 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗗𝗮𝘆 𝟮𝟬𝟮𝟱, held at 𝗣𝗲𝗿𝗱𝗮𝗻𝗮 𝗞𝘂𝗮𝗹𝗮 𝗟𝘂𝗺𝗽𝘂𝗿 𝗖𝗶𝘁𝘆 𝗖𝗲𝗻𝘁𝗿𝗲 on 𝟭𝟱–𝟭𝟲 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿, in support of the growing impact of 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗰𝗼𝘂𝗻𝘀𝗲𝗹𝗹𝗶𝗻𝗴 𝗶𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲.
The event brought together clinicians, genetic counsellors, patients, and students to explore how 𝗵𝗲𝗿𝗲𝗱𝗶𝘁𝗮𝗿𝘆 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 — from 𝗰𝗮𝗿𝗿𝗶𝗲𝗿 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 to 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 — is reshaping care pathways and ethical considerations in practice.
🧬 At our booth, we showcased the power of 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗥𝗶𝘀𝗸 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 through our 𝗖𝗔𝗡𝗖𝗘𝗥𝗜𝗦𝗞® 𝗽𝗮𝗻𝗲𝗹 and 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗲𝘀𝘁𝘀, designed to provide 𝗲𝗮𝗿𝗹𝘆, 𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀.
☕ A highlight was our 𝗺𝗼𝗿𝗻𝗶𝗻𝗴 𝘁𝗲𝗮 𝘁𝗮𝗹𝗸 by Dr Muzhirah Aisha, sharing how 𝗪𝗵𝗼𝗹𝗲 𝗘𝘅𝗼𝗺𝗲 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 (𝗪𝗘𝗦) uncovered a novel mutation, improving diagnostic clarity and guiding more precise, personalised care.
Thank you to everyone who stopped by, listened, and shared. Together, we’re shaping the future of 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗮𝗻𝗱 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮.
31/12/2025
Wishing you a healthy and peaceful year ahead.🫶🏻✨
May 2026 bring strength, healing, and calm to every day.🌿
— Oncode Scientific
24/12/2025
May this joyful season bring hope, health, and peace to us all ✨
Wishing you a Merry Christmas 🎄
— Oncode Scientific
12/12/2025
On 8th November 2025, we were honoured to take part in the 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝗕𝗮𝗰𝗸 𝘁𝗼 𝗕𝗮𝘀𝗶𝗰𝘀, held in conjunction with 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵.
The workshop emphasised how 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 supports lung cancer care, from the foundations of histopathological evaluation to guiding treatment decisions based on driver mutations detected in advanced disease.
At Oncode Scientific, our mission is clear — to deliver 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲, 𝘁𝗶𝗺𝗲𝗹𝘆, 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 that empower physicians and improve outcomes. From 𝘁𝗶𝘀𝘀𝘂𝗲 𝘁𝗼 𝗹𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝘆, our lung cancer panels are built to support real-world clinical decisions.
Thank you to all the organisers and healthcare professionals who continue to champion education and innovation in cancer care.
25/11/2025
We had an incredible experience at the 𝟯𝟲𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝟮𝟬𝟮𝟱 (𝗔𝗦𝗖𝗢𝗠𝗢𝗦 𝟮𝟬𝟮𝟱), engaging with oncologists, internal medicine physicians, surgeons, pathologists, researchers, and other healthcare professionals who share our passion for advancing cancer care. The conference offered a unique opportunity to explore cutting-edge diagnostics, therapeutics, and technologies shaping the future of oncology.
🧬 We were proud to participate in the poster presentation, sharing real-world findings from our 𝗡𝗚𝗦-𝗯𝗮𝘀𝗲𝗱 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 and highlighting how molecular insights guide personalised treatment decisions.
🤝 Our collaborations with pharmaceutical partners reflect a shared commitment to advancing precision oncology — from supporting clinical trials to developing companion diagnostics that enable faster, more informed treatment decisions.
🚀 Driven by continuous R&D, we’re expanding access to 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 and elevating the standard of 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 for patients across Malaysia.
A heartfelt thank you to everyone who visited and engaged with us — your passion inspires our mission to make precision cancer care more accessible and impactful.
14/11/2025
We will be at 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗖𝗼𝘂𝗻𝘀𝗲𝗹𝗹𝗼𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗗𝗮𝘆 𝟮𝟬𝟮𝟱 (𝗚𝗖𝗔𝗗 𝟮𝟬𝟮𝟱)! Drop by the Oncode booth to explore reliable genomic solutions for confident, informed clinical decisions.
Check out our morning tea break talk on 𝗛𝗼𝘄 𝗪𝗵𝗼𝗹𝗲 𝗘𝘅𝗼𝗺𝗲 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 𝗥𝗲𝗳𝗶𝗻𝗲𝘀 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀, delivered by Dr. Muzhirah Aisha Haniffa.
📅 Date: 15 November 2025
⏰ Time: 8:00AM – 5:00PM
📍 Location: Pearl & Amethyst Hall, Perdana Hotel Kuala Lumpur
10/11/2025
As part of a collaborative continuing medical education (CME) session with Astellas, Oncode had the opportunity to engage with the enthusiastic 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗛𝗮𝗲𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝘁𝗲𝗮𝗺 𝗮𝘁 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗦𝘂𝗹𝘁𝗮𝗻 𝗔𝗯𝗱𝘂𝗹 𝗔𝘇𝗶𝘇 𝗦𝗵𝗮𝗵, 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝗶 𝗣𝘂𝘁𝗿𝗮 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 (𝗛𝗦𝗔𝗔𝗦 𝗨𝗣𝗠) on 4th August 2025.
The session covered key insights into 𝗙𝗟𝗧𝟯 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀 (𝗙𝗟𝗧𝟯𝗺), the most common genetic alterations in 𝗔𝗰𝘂𝘁𝗲 𝗠𝘆𝗲𝗹𝗼𝗶𝗱 𝗟𝗲𝘂𝗸𝗲𝗺𝗶𝗮 (𝗔𝗠𝗟), and compared available testing methods, outlining their clinical applications and limitations. We underscored the need for 𝗿𝗮𝗽𝗶𝗱 𝘁𝘂𝗿𝗻𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗶𝗺𝗲 in guiding timely, effective treatment, and showcased 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 highlighting the role of 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 in AML management.
The session also spotlighted the 𝗙𝗟𝗧𝟯𝗺 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗖𝗼𝗽𝗮𝘆 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝗯𝘆 𝗢𝗻𝗰𝗼𝗱𝗲 & 𝗔𝘀𝘁𝗲𝗹𝗹𝗮𝘀, providing 𝘀𝘂𝗯𝘀𝗶𝗱𝗶𝘀𝗲𝗱 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 for HSAAS UPM patients with relapsed or refractory AML.
Grateful for the meaningful discussions and shared commitment to advancing precision haematology.
24/10/2025
🌆 𝗢𝗻𝗰𝗼𝗱𝗲 𝗮𝘁 𝗡𝗕𝗶𝗼𝗦𝗛𝗢𝗪𝗖𝗔𝗦𝗘, 𝗜𝗗𝗘𝗖𝗦𝟮𝟱 𝗦𝗮𝗿𝗮𝘄𝗮𝗸 🌆
We are honoured to be part of 𝗡𝗕𝗶𝗼𝗦𝗛𝗢𝗪𝗖𝗔𝗦𝗘 𝟮𝟬𝟮𝟱, held in conjunction with 𝗜𝗗𝗘𝗖𝗦𝟮𝟱 in Sarawak — where innovators, researchers, and changemakers came together to reimagine the future of bioeconomy and technology.
We are also delighted to have our 𝗙𝗼𝘂𝗻𝗱𝗶𝗻𝗴 𝗖𝗘𝗢, 𝗔𝘀𝘀𝗼𝗰. 𝗣𝗿𝗼𝗳. 𝗗𝗿. 𝗦𝘂 𝗪𝗲𝗻 𝗟𝗶𝗺, invited as a speaker at 𝗜𝗗𝗘𝗖𝗦𝟮𝟱, where she delivered an inspiring reflection titled “Healing the Future City: Building Health Systems That Think, Adapt & Care.”
In her keynote, Dr. Lim reminded audiences that as nations race to build smarter and more connected cities, true progress cannot be measured by speed, scale, or technology alone — but by the health and well-being of the people who live within them.
She urged a redefinition of progress: from technology as a competition of advancement, to technology as an act of healing — one that restores balance between people, planet, and progress. Because the future city is not just smart — it must also be compassionate.
At Oncode, this belief forms the foundation of everything we do.
We are building technologies that heal, restore, and uplift humanity — systems that think intelligently, adapt naturally, and care deeply.
💡 “Technology is not about invention for its own sake, nor competition for prestige — its very reason to exist is to heal, restore, and uplift lives.” — 𝗔𝘀𝘀𝗼𝗰. 𝗣𝗿𝗼𝗳. 𝗗𝗿. 𝗦𝘂 𝗪𝗲𝗻 𝗟𝗶𝗺
We extend our heartfelt thanks to Bioeconomy Corporation for the kind invitation and for hosting us. We deeply value the opportunity to share our vision among fellow innovators and changemakers who are shaping a future where science and technology work hand in hand to improve lives.
19/10/2025
✨ Wishing everyone a bright and joyful Deepavali!
May this Festival of Lights remind us that even the smallest glow can illuminate the world. 🌠
15/10/2025
We’re honoured that our Founding CEO, Assoc. Prof. Dr. Su Wen Lim, was invited as one of the distinguished panelists at BioXCeed 2025, held in conjunction with The National Innovation and Commercialisation Expo (NICE 2025) by Kementerian Sains, Teknologi dan Inovasi (MOSTI).
Under the BioXCeed 2025 segment — jointly driven by MTDC and Bioeconomy Corporation, the event showcases cutting-edge deep-tech and bioeconomy solutions, bringing together innovators, investors, and industry leaders driving Malaysia’s bioeconomy forward.
Dr. Lim joined the panel discussion on “𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗦𝘂𝗰𝗰𝗲𝘀𝘀: 𝗕𝗲𝘆𝗼𝗻𝗱 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮’𝘀 𝗕𝗼𝗿𝗱𝗲𝗿𝘀”, moderated by En. Norazil Mohamad Nor (Xeraya Capital), alongside esteemed speakers Dr. Faizal Hamid (Bioeconomy Corporation), Ts. Dr. Indera Shaiful Baharudin, PhD (Malaysian Technology Development Corporation (MTDC)), and Noor Shazreena Ishak (Bio-Angle Vacs Sdn. Bhd.).
Dr. Lim shared Oncode’s journey from a small Malaysian molecular diagnostics lab into a regional precision medicine group — highlighting how innovation, credibility, and ecosystem support empower local MSMEs to scale beyond borders.
A heartfelt thanks to Bioeconomy Corporation for the kind invitation, and to MOSTI, Bioeconomy Corporation and Malaysian Technology Development Corporation (MTDC), for hosting this impactful platform championing Malaysia’s innovation and bioeconomy landscape. 🌍
14/10/2025
On 1st October 2025, Oncode conducted a CME session at the 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗥𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗗𝗲𝗽𝗮𝗿𝘁𝗺𝗲𝗻𝘁, 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗖𝗮𝗻𝘀𝗲𝗹𝗼𝗿 𝗧𝘂𝗮𝗻𝗸𝘂 𝗠𝘂𝗵𝗿𝗶𝘇 (𝗛𝗖𝗧𝗠 𝗨𝗞𝗠) on the topic “𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗡𝗚𝗦 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲.”
The session provided an in-depth comparison between 𝗣𝗖𝗥 𝗮𝗻𝗱 𝗡𝗚𝗦 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 in lung cancer profiling, highlighting their impact on 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀. It also addressed the 𝗯𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝘀, 𝗱𝗮𝘁𝗮 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀, 𝗮𝗻𝗱 𝗿𝗶𝗴𝗼𝗿𝗼𝘂𝘀 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 in ensuring precision within molecular laboratories.
Participants were also introduced to Oncode’s 𝘀𝘂𝗯𝘀𝗶𝗱𝗶𝘀𝗲𝗱 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗽𝗿𝗼𝗴𝗿𝗮𝗺, 𝗛𝗥𝗗 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗳𝗼𝗿 𝗼𝘃𝗮𝗿𝗶𝗮𝗻 𝗰𝗮𝗻𝗰𝗲𝗿, 𝗮𝗻𝗱 𝗹𝗶𝗾𝘂𝗶𝗱/𝘁𝗶𝘀𝘀𝘂𝗲 𝗯𝗶𝗼𝗽𝘀𝘆 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 across multiple cancer types.
Thank you to the HCTM team for your engagement and commitment to advancing personalised oncology care.
Address
Lot 03-01, 3rd Floor. Hap Seng Business Park, No. 12, Persiaran Perusahaan, Unity Square. Seksyen 23, Shah Alam D. E. Shah Alam 40300
Be the first to know and let us send you an email when Oncode Scientific Sdn Bhd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
ONCODE Scientific Sdn Bhd was founded in 2015, by a strong knowledge-based management and operational team with the combination of more than 85 years of experience in the areas of medical diagnostics and scientific research. It’s aims to be a niche player specializing in Precision Medicine utilizing the techniques of Next Generation Sequencing (NGS), Sanger sequencing, Real-Time & Standard PCR technologies. The team comprises of scientists, geneticists, physicians, pharmacists, bioinformaticians and business veterans who aim to deliver the best quality and affordable molecular diagnostic solutions to the global community.
Oncode laboratory workflows and pipelines include internal and external validation quality controls for compliance with international standards of Good Laboratory Practice (GLP), ISO 15189, the Association for Molecular Pathology (AMP) and the College of American Pathologist (CAP).
The laboratory participates in external quality assurance and proficiency programs including the UK National External Quality Assurance System (UKNEQAS), The European Molecular Genetics Quality Network (EMQN) and the Royal College of Pathologists of Australasia (RCPA).
Oncode Mission
To provide quality diagnostic solutions to customers through the implementation of state-of-the-art laboratory setup designed to worldwide standards, recruitment of dedicated professionals and comprehensive reporting systems.
Oncode Objective
To be a regional one-stop molecular genetics solution center, delivering powerful diagnostic support and insight to medical professionals
恩可德实验室工作流程和管道包括内部和外验证质量控制，以符合良好实验室规范(Good- Laboratory Practice, GLP)，国际标准化组织（ISO15189），分子病理学协会(Association of Molecular Pathology, AMP)和美国病理学家学会(College of American Pathologist, CAP)的国际标准。
该实验室参与外部质量保证和熟练程序，包括英国国家外部质量保证体系(United Kingdom National External Quality Assurance System, UKNEQAS)，欧洲分子遗传学质量网络(European Molecular Genetics Quality Network)和澳大利亚皇家病理学家学会(Royal College of Pathologists of Australasia, RCPA).
